Hos patienter med knoglemetastaser var andelen af patienter, som udviklede en ny knoglerelateret hændelse, mindre med Zometa (33- 38%) end med placebo (44%).
In patients with bone metastases, the proportion of patients who developed a new skeletal event was lower with Zometa (33 to 38%) than with placebo (44%).